Willem de Haan, MD, PhD, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands, comments on the implementation of EEG as a functional endpoint in Alzheimer’s disease (AD) clinical trials. His team have been running an EEG lab for central EEG analysis for large, multicenter, clinical trials for over a decade. For trials incorporating EEG as an outcome measure, the lab advises on how often to record EEGs, technical requirements, and provides manuals, instructions, and coaching to the clinical trial sites. Prior to the trial, participating sites are required to produce high-quality EEG data that meets specific standards. During the trial, resting-state EEGs are sent to the lab where they are quality checked and ideal segments are selected through experienced visual analysis. Once the EEG dataset is complete, a quantitative analysis is conducted using specialized software which measures various markers relevant to the study’s outcomes. This interview took place at the Clinical Trials on Alzheimer’s Disease (CTAD) congress 2023 in Boston.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
